Gamma-Hydroxybutyrate Formulation with pH-Dependent Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modified release formulations of sodium oxybate for narcolepsy have low bioavailability and inconvenient dosing regimens, requiring multiple daily administrations and high sodium intake, which can lead to adverse effects and poor patient compliance.
Innovation Solution
A novel modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in acidic medium and the other half in phosphate buffer, achieving bioavailability comparable to twice-nightly immediate release liquid solutions, allowing for once-nightly administration with reduced side effects and sodium content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of sodium oxybate are used, then dosing convenience is improved (once nightly), but bioavailability is reduced and therapeutic effectiveness is compromised
Solution Approach 1:
The formulation segments gamma-hydroxybutyrate into two distinct release mechanisms: an immediate release portion (40-80% of total dose) that rapidly dissolves in acidic gastric environment, and a modified release portion (20-60% of total dose) that dissolves in intestinal phosphate buffer environment. This segmentation allows the drug to achieve both convenient once-nightly dosing and high bioavailability by mimicking the pharmacokinetic profile of twice-nightly immediate release dosing.
Solution Approach 2:
The invention changes the dissolution parameters of gamma-hydroxybutyrate by using pH-dependent release mechanisms. The immediate release portion dissolves at gastric pH (acidic environment), while the modified release portion dissolves at intestinal pH (phosphate buffer environment). This parameter change based on pH allows optimized absorption at different gastrointestinal locations, resolving the contradiction between dosing convenience and bioavailability.
2Reliability
If conventional immediate release liquid solution is used, then bioavailability is maintained, but sodium intake is excessive and adverse effects increase
Solution Approach 1:
The invention changes the chemical form of gamma-hydroxybutyrate from sodium salt to other pharmaceutically acceptable salts (potassium, calcium, magnesium, or zinc salts) or free acid form. This parameter change maintains the therapeutic effectiveness and bioavailability while reducing sodium intake and associated adverse effects such as hypertension and edema.
3Reliability
If multiple daily administrations are required, then therapeutic effectiveness is maintained, but patient compliance deteriorates
Solution Approach 1:
The formulation segments the dosing regimen into a single once-nightly administration that combines both immediate release and modified release portions. This segmentation of release mechanisms within a single dose allows the drug to provide sustained therapeutic effectiveness throughout the night and into the morning, eliminating the need for multiple administrations and improving patient compliance.
Solution Approach 2:
The modified release portion provides continuous release of gamma-hydroxybutyrate over an extended period (8-12 hours), ensuring continuous therapeutic action. This continuity of useful action maintains therapeutic effectiveness while allowing once-nightly dosing, thereby improving patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides improved bioavailability and therapeutic effectiveness with reduced adverse reactions, allowing for a convenient once-nightly dosing regimen and lower sodium intake, enhancing patient compliance and safety.
Implementation Method 1
rapidly releases half of its dose in acidic medium and the other half in phosphate buffer
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.